INS 1007

Drug Profile

INS 1007

Alternative Names: AZD 7986; INS1007

Latest Information Update: 24 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Insmed
  • Class Anti-inflammatories; Antibronchitics; Small molecules
  • Mechanism of Action Dipeptidyl peptidase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bronchiectasis; Chronic obstructive pulmonary disease

Most Recent Events

  • 21 May 2018 INSMED has patent protection for INS 1007 in USA
  • 12 Feb 2018 Phase-II clinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO) (AstraZeneca pipeline, February 2018)
  • 30 Jan 2018 Phase-II clinical trials in Bronchiectasis in Sweden (PO) (EudraCT2017-002533-32)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top